160 HEALTH

Health160 (2656.HK) opened low and rallied higher in the morning session, up 5.16% to HKD 11.20 by 9:48 BJ, fully recovering from yesterday's close of HKD 10.65. The intraday range spanned HKD 10.73-11.20, with a 4.4% amplitude, reflecting continued AI healthcare momentum in Hong Kong. The company recently disclosed expanding AI hospital collaborations, which previously drove a 45.64% single-day surge, yet the stock has retreated 92.93% from its March 52-week high of HKD 158.4 and is down 80.9% YTD, still trading below its 60-day MA of HKD 12.772. Q4 2025 revenue reached HKD 201 million (+8.85% YoY), but net loss widened 124.1% to HKD 30 million, with EPS of -HKD 0.0955 and a PE of -48.13x. However, today's trading volume of only 511,250 shares translates to a turnover rate of 0.15%, indicating thin liquidity.

160 Health International opened lower at HK$10.85 in the morning session but rallied sharply, hitting an intraday high of HK$11.13 within five minutes, up 5.0% from the prior close of HK$10.60. However, it remains a staggering 92.97% below its 52-week high of HK$158.4 and has tumbled 81.02% YTD. The surge is attributed to reports that the company's AI operations have broken through three major barriers in hospital collaboration, achieving a monthly compound growth rate of 155.7% in single-hospital GMV. The stock has also drawn renewed attention from the AI healthcare theme and its inclusion in the Hong Kong Stock Connect, following previous single-day rallies of over 40%. However, earnings for Q4 2025 showed revenue growth of 8.85% y/y to HK$200.8 million, but net loss widened 124.1% y/y to HK$29.95 million, with EPS of -HK$0.0955. The stock trades at a PE of -47.83x and a PB of 14.6x. While the current price sits above the 20-day MA (HK$10.111), it remains well below the 60-day MA (HK$12.979), and the recent issuance of 10.79 million new shares under a pre-IPO option scheme adds potential dilution.

The stock gapped up sharply during today's trading session, opening at HK$10.12, nearly flat from the previous close of HK$10.11, before quickly surging to an intraday high of HK$10.75 and closing at HK$10.68, up 5.64%. The sharp move was primarily driven by renewed AI healthcare sector momentum and a technical rebound following deep recent declines. The morning session was highly volatile, with a swing of 8.4% between the intraday high (10:42 BJ) and low (09:31 BJ). Despite a 8.85% YoY increase in Q4 2025 revenue to HK$200.8 million, the net loss deepened 124.1% YoY to HK$29.95 million, with EPS of -HK$0.0955, underscoring deteriorating fundamentals. The stock remains 93.26% below its 52-week high of HK$158.4, up 15.46% from its 52-week low of HK$9.25, and trades well below the MA60 (HK$13.062), with a YTD decline of 81.79%. The price position is extremely weak, and the PB ratio of 14.01x remains elevated. However, trading volume of 1.11 million shares and a turnover rate of just 0.32% suggest limited conviction behind the move.

2656.HK opened low and staged a strong intraday rebound during the morning session, rallying from a low of HK$9.500 to close at HK$10.150, up 5.1% on volume of 591,750 shares and turnover of HK$5.91 million, primarily driven by AI healthcare momentum and recent operational milestones. The company's 160 Health platform reported a 155.7% monthly compound growth rate in hospital GMV and 80% gross margins in AI business, sparking investor interest. However, its Q4 net loss widened by 124.1% YoY to approximately HK$29.95 million, while revenue grew only 8.85% to HK$200.8 million, underscoring ongoing profitability challenges. The stock remains 93.59% below its 52-week high of HK$158.400, trades below the 60-day moving average of HK$13.143, and has declined 82.69% year-to-date, suggesting the rebound is occurring against a backdrop of deep valuation erosion.

160 Health tumbled in the afternoon session to close down 5.0% at HK$9.86, a record low, 93.8% below its 52-week high of HK$158.4 and down 83.2% year-to-date. The drop was triggered by a HKEX next-day filing revealing 10,787,770 new shares issued under a pre-IPO option scheme, compounding dilution fears, while Q4 2025 net loss widened 124.1% YoY to HK$29.95 million despite 8.85% revenue growth. The stock briefly rallied to HK$10.52 in the morning, suggesting lingering speculative interest in AI healthcare, but has since fallen below both the MA20 (HK$10.10) and MA60 (HK$13.59), underscoring persistent weakness.